US2017216412A1PendingUtilityA1

Recombinant human naglu protein and uses thereof

Assignee: ALEXION PHARMA INCPriority: Oct 12, 2011Filed: Feb 10, 2017Published: Aug 3, 2017
Est. expiryOct 12, 2031(~5.2 yrs left)· nominal 20-yr term from priority
A61P 37/06A61P 43/00A61P 7/02A61P 3/00A61P 25/20A61K 9/0019A61P 19/02C12N 9/2474A61P 1/12A61P 17/00A61K 38/47A61P 25/00C12Y 302/0105C12N 9/2402A61K 45/06C07K 7/08A61P 1/00A61P 1/02A61K 31/7024A61P 1/16C07K 7/06
45
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides compositions comprising an isolated mixture of recombinant human NaGlu proteins in which a substantial amount of the NaGlu proteins in the mixture has increased levels of phosphorylated mannose that confer the proteins to be efficiently internalized into human cells. The present invention also provides methods of producing such mixture of NaGlu proteins, vectors used in transgenesis and expression, host cells harboring such vectors, and methods of isolating and purifying the mixture of NaGlu proteins. The invention further provides methods of treating NaGlu associated diseases.

Claims

exact text as granted — not AI-modified
1 . A composition comprising an isolated mixture of recombinant human N-acetyl-5 alpha-D-glucosaminidase (rhNaGlu) comprising the amino acid sequence 24-743 of SEQ ID NO: 1, wherein at least 10% of said rhNaGlu in said mixture comprises at least one glycan structure having mannose-6-phosphate (M6P). 
     
     
         2 .- 16 . (canceled) 
     
     
         17 . A method of producing a recombinant human NaGlu (rhNaGlu) comprising:
 a) producing a transgenic avian comprising a trans gene having a promoter component operably linked to a nucleic acid sequence encoding the rhNaGlu set forth in 24-743 of SEQ ID NO:1, wherein said transgene is contained in the genome of the transgenic avian and expressed in an oviduct cell, such that the rhNaGlu is glycosylated in the oviduct cell of the transgenic avian, secreted into lumen of oviduct and deposited in egg white of an egg laid of the transgenic avian; and   b) isolating said rhNaGlu from said egg white.   
     
     
         18 .- 29 . (canceled) 
     
     
         30 . A method of delivering recombinant human NaGlu protein to the brain of a subject suffering from NaGlu deficiency, the method comprising intravenously administering recombinant human NaGlu protein to the subject.

Join the waitlist — get patent alerts

Track US2017216412A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.